Skip to main content
Signal8
Launch Terminal
Ellias Helen K. profile photo

Helen K. Ellias

CIK: 0002001600

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

SAB Biotherapeutics, Inc. logo
SABS

SAB Biotherapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (3 total)

  • SAB Biotherapeutics, Inc. logo
    SABS

    SAB Biotherapeutics, Inc.

    Dec 16, 2025
    Award(A)

    Stock Option (right to buy)

    Direct
    150K shares-
  • SAB Biotherapeutics, Inc. logo
    SABS

    SAB Biotherapeutics, Inc.

    Nov 1, 2024
    Award(A)

    Stock Option (right to buy)

    Direct
    20K shares-
  • SAB Biotherapeutics, Inc. logo
    SABS

    SAB Biotherapeutics, Inc.

    Nov 1, 2024
    Award(A)

    Stock Option (right to buy)

    Direct
    35K shares-

1-3 of 3

About Ellias Helen K.

Ellias Helen K. (SEC CIK 0002001600) files insider reports with the SEC as Director of SAB Biotherapeutics, Inc. (SABS).

Signal8 holds 2 ownership filings by Ellias Helen K., all Form 4s, filed between Nov 5, 2024 and Dec 18, 2025. Those filings report 3 transactions, from Nov 1, 2024 to Dec 16, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on Ellias Helen K.'s filings is in MIAMI BEACH, FL.

Recent filings by Ellias Helen K.

  • Dec 16, 2025: Grant or award of SABS derivative securities (Form 4, code A).
  • Nov 1, 2024: Grants or awards of SABS derivative securities (2 lines, Form 4, code A).

Other insiders filing for SAB Biotherapeutics, Inc. (SABS)

How to read Form 4 transaction codes